Skip to main content
. 2015 May 14;4(5):e001986. doi: 10.1161/JAHA.115.001986

Figure 4.

Figure 4

Activity of NRF2 in skeletal muscle of CLI patients. A, Represents mRNA expression of NRF2 in the skeletal muscle of control and CLI patients. B, Represents immunoblots of nuclear levels of NRF2 and fibrillarin in the skeletal muscle of control and CLI patients. C, Quantitation of immunoblots in (B). D, NRF2-DNA binding activity as judged by EMSA; lanes 1 and 2, control; lanes 3 and 4, CLI. E, The binding specificity of NRF2; lane 1, free probe; lane 2, NE; lane 3, NE+W/T oligo (250× excess); lane 4, NE+NRF2 antibody; and lane 5, NE+nonspecific antibody (non sp. ab). Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; EMSA, electrophoretic mobility shift assay; NE, nuclear extracts; NRF2, nuclear factor-erythroid 2-related factor 2; W/T, wild type.